Journal Article Review Ahead of print
PubMed: 42119664 DOI: 10.1016/j.anai.2026.05.006
The Monoclonals: What have we learned and where are we going?
Ann Allergy Asthma Immunol
Authors: Amber N Pepper, Thomas B Casale
Affiliations
- Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
- Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Abstract
Since the approval of the first biologic for the treatment of for allergic and immunologic diseases in 2003, the era of monoclonal antibodies has expanded. In this review, we explore technological updates that have improved the utility of monoclonal antibodies for the management of allergic and respiratory diseases. These improvements include the development of fully, versus previously partially, humanized monoclonal antibodies, the approval of biosimilars, the utility of mutations in the Fc portion of monoclonal antibodies that allow for longer duration of action with an extended half-life, the development of bispecific and trispecific monoclonal antibodies and nanobodies, antibody drug conjugates, and novel approaches to degrade proteins that are critical in the pathogenesis of these diseases. Emerging monoclonals will target IgE, mast cells, and other innovative targets through these various strategies. The current monoclonal antibodies have been invaluable to help understand disease pathogenesis, provide better therapies, and identify novel targets. The next generation should provide safer, longer lasting and more effective options. However, better biomarkers and outcomes data are still needed to more effectively match the best approach for each patient.
MeSH
Antibodies, Hypersensitivity, Immunity, Antibodies, Monoclonal, Therapeutics, Asthma